The Conversation (0)
M Pharmaceutical (CSE:MQ) announced the appointment of Dr. Christopher Andrews, M.D., MSc, FRCPC, to the Board of Directors. Dr. Andrews is a specialist in the field of stomach disorders and physiology.
As quoted in the press release:
Dr. Christopher Andrews, M.D., MSc, FRCPC, a highly-respected Gastroenterologist, faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN, is joining the Board of Directors of M Pharmaceutical Inc. (the “Company”) (CSE:MQ).
Dr. Andrews, who specializes in stomach disorders and physiology, is the latest leadership asset to join the Company, which is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity or diabetes.
“We’re delighted to have someone of Dr. Andrews’ background and profile join our organization and help us advance our vision for biomedical technologies designed to improve the lives of those dealing with obesity and diabetes,” said Dr. Martin Mintchev, the President & Chief Executive Officer of the Company. “His addition to our Board of Directors will help ensure that we make the most of our vision and strategic plan reflected in technologies such as the e-Mosquito wearable blood glucose monitor, the implantable gastro-intestinal neuro stimulators and the ingestible pseudobezoars.”
Dr. Andrews is a Clinical Associate Professor at the University of Calgary. He has had advanced training in gastrointestinal motility and function at the Mayo Clinic, where he also obtained a Masters Degree in Clinical Health Research. Dr. Andrews also specializes in the development of novel diagnostic and therapeutic methods related to gut function. He went to McMaster Medical School, followed by residencies in Internal Medicine and Gastroenterology at the University of British Columbia and University of Calgary, respectively.
Dr. Andrews has won many awards, including a Young Investigator Award from the American Motility Society for his research on the effects of glucagon-like peptide-1 on gastric accommodation, and is currently the Canadian Association of Gastroenterology Visiting Clinical Professor. He has published over 50 peer-reviewed articles and has numerous teaching citations from the University of Calgary Medical School.
Dr. Mintchev also acknowledged the contributions of David Lane of Coquitlam, B.C. to the growth and development of the Company: “We’re in a strong position to continue our growth and fulfil our vision thanks largely to the work of David Lane as our inaugural President of the Company. As he leaves the board, we wish him all the best in his new endeavours and thank him for his service.”
Click here to read the M Pharmaceutical Inc (CSE:MQ) press release
Click here to see the M Pharmaceutical Inc (CSE:MQ) profile.